for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AtriCure Inc.

ATRC.OQ

Latest Trade

26.65USD

Change

0.30(+1.12%)

Volume

93,252

Today's Range

26.32

 - 

26.78

52 Week Range

22.57

 - 

34.37

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
26.35
Open
26.32
Volume
93,252
3M AVG Volume
5.58
Today's High
26.78
Today's Low
26.32
52 Week High
34.37
52 Week Low
22.57
Shares Out (MIL)
38.78
Market Cap (MIL)
1,021.92
Forward P/E
-30.08
Dividend (Yield %)
--

Next Event

Q3 2019 AtriCure Inc Earnings Release

Latest Developments

More

Atricure Enters Into Definitive Agreement To Acquire Sentreheart

AtriCure Reports Q2 Adjusted Loss Per Share $0.17

Atricure Reports Q1 Adj Loss Per Share Of $0.20

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AtriCure Inc.

AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

Industry

Medical Equipment & Supplies

Contact Info

7555 Innovation Way

+1.513.7554100

https://www.atricure.com

Executive Leadership

Scott William Drake

Independent Chairman of the Board

Michael H. Carrel

President, Chief Executive Officer, Director

Andrew Wade

Chief Financial Officer, Senior Vice President

Douglas J. Seith

Chief Operating Officer

Justin J. Noznesky

Senior Vice President, Marketing and Business Development

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.2K

2018

0.2K

2019(E)

0.2K
EPS (USD)

2016

-1.050

2017

-0.960

2018

-0.620

2019(E)

-0.876
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.74
Price To Book (MRQ)
4.23
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
24.10
LT Debt To Equity (MRQ)
23.83
Return on Investment (TTM)
-7.88
Return on Equity (TTM)
-7.02

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up